The application of visceral adiposity index in identifying type 2 diabetes risks based on a prospective cohort in China by Chen Chen et al.
Chen et al. Lipids in Health and Disease 2014, 13:108
http://www.lipidworld.com/content/13/1/108RESEARCH Open AccessThe application of visceral adiposity index in
identifying type 2 diabetes risks based on a
prospective cohort in China
Chen Chen1,2†, Yan Xu3†, Zhi-rong Guo4, Jie Yang2, Ming Wu1,2,6* and Xiao-shu Hu1,5,6*Abstract
Background: Visceral adiposity index (VAI), a novel sex-specific index for visceral fat measurement, has been
proposed recently. We evaluate the efficacy of VAI in identifying diabetes risk in Chinese people, and compare the
predictive ability between VAI and other body fatness indices, i.e., waist circumference (WC), body mass index (BMI)
and waist- to- height ratio (WHtR).
Methods: Participants (n = 3,461) were recruited from an ongoing cohort study in Jiangsu Province, China. Hazard
ratio (HR) and corresponding 95% confidence interval (CI) between diabetes risk and different body fatness indices
were evaluated by Cox proportional hazard regression model. Receiver operating characteristic (ROC) curve and
area under curve (AUC) were applied to compare the ability of identifying diabetes risk between VAI, WC, WHtR
and BMI.
Results: A total number of 160 new diabetic cases occurred during the follow-up, with an incidence of 4.6%.
Significant positive associations were observed for VAI with blood pressure, fasting plasma glucose, triglyceride, WC,
BMI and WHtR. Moreover, increased VAI was observed to be associated with higher diabetes risk with a positive
dose–response trend (p for trend < 0.001). As compared to individuals with the lowest VAI, those who had the
highest VAI were at 2.55-fold risk of diabetes (95% CI: 1.58-4.11). The largest AUC was observed for VAI, following by
WC, WHtR and BMI.
Conclusions: VAI is positively associated with the risk of diabetes. Compared to other indices for body fatness
measurements, VAI is a better and convenience surrogate marker for visceral adipose measurement and could be
used in identifying the risk of diabetes in large-scale epidemiologic studies.
Keywords: Diabetes, Visceral adiposity index, Body mass index, Waist circumference, Waist-to-height ratioIntroduction
Diabetes has become a worldwide public health problem
seriously threatening human health [1]. There was a rapid
rising trend in the prevalence of diabetes in China during
the past decades [2]. The results of 2007–2008 National
Diabetic Epidemiological Survey showed that the preva-
lence of diabetes in China was 9.7%, and estimated that
the number of Chinese diabetic patients is 92.4 million,* Correspondence: jswuming@vip.sina.com; huxs@jsfda.gov.cn
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unless otherwise stated.which indicates that China is not only a region with the
fastest growing speed of diabetes, but also is the country
with the largest diabetes population [3].
Many studies have confirmed that obesity plays an im-
portant role in the development of diabetes. Excess fat
may lead to insulin resistance (IR) and abnormal glucose
metabolism [4,5]. Oti et al. found that obesity is closely re-
lated to high blood glucose particularly among African
women [6]. Matsuda summarized that adipose tissue is a
main source of reactive oxygen species, which may con-
tribute to the development of obesity-associated IR and
cause type 2 diabetes as a consequence [7]. However,
obese people may vary in their body fat distribution and
disease risk, and regional adipose tissue distribution wastd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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adiposity and glycometabolism. It is reported that individ-
uals with high visceral adiposity are associated with in-
creased risks of IR and metabolic disorders, and are more
likely to suffer from diabetes [8,9]. Bu et al. found that
average IR in visceral obesity group was significant higher
than that in non-obese group [10].
In most studies, body fat was measured by waist cir-
cumference (WC), body mass index (BMI) and waist-
to-height ratio (WHtR), but these indices are not able to
distinguish between subcutaneous fat and visceral fat
[11]. For instance, even with BMI in normal range, indi-
viduals may still have high level of visceral adipose tissue
(VAT). For measuring the volume of visceral fat, mag-
netic resonance imaging (MRI) and computed tomog-
raphy (CT) has been recognized as the gold standard for
quantitative detection [12], however, these two methods
are inconvenience and expensive, and are obviously not
suitable for large-scale epidemiological studies. Recently,
Amato et al. proposed a novel sex-specific index for vis-
ceral fat measurement, which is calculated on the basis
of WC, BMI, triglyceride (TG) and high density lipopro-
tein cholesterol (HDL-C), and is termed as visceral adi-
posity index (VAI). They observed that VAI was highly
correlated with body visceral adiposity measured by MRI
[13]. VAI combined both physical and metabolic param-
eters to evaluate body fatness, which may reflect visceral
adiposity better than other indices. Bozorgmanesh et al.
found that VAI has good prediction effect on diabetes in
Tehran people [14]. Although VAI has been suggested as
a useful and convince surrogate marker for visceral adi-
posity, it’s efficacy in predicting diabetes risk still needs
to be further confirmed, moreover, no previous studies
have been conducted among Chinese population. In this
study, we took advantage of an ongoing prospective
study in Jiangsu Province, China; it aims to further
evaluate the efficacy of using VAI to identify diabetes
risk in Chinese people, and to compare the risk predict-
ive ability between VAI and other body fatness indices,
i.e., WC, BMI and WHtR.
Materials and methods
Study population
The study of Prevention of Multiple Metabolic Disorders
and Metabolic Syndrome in Jiangsu Province is an on-
going prospective cohort study aimed to estimate the
prevalence of metabolic syndrome (MS) and the incidence
of type 2 diabetes in Jiangsu Province, China. The study
design has been previously described in detail [15-18].
Briefly, this cohort has been established since early 2000s
in Jiangsu. A total number of 6,400 participants aged
35–74 years was randomly selected for the baseline survey
by a multi-stage sampling method, and 92% of them
(n = 5,888) completed the first round survey.During 2006–2009, subjects (n = 4,582) who had already
been followed up for more than 5 years were invited for
the second round survey and 3,847 subjects participated.
As the primary endpoint of this study was the occurrence
of diabetes, we excluded subjects who have been diag-
nosed with diabetes at baseline. In total, 3,461 subjects
completed the follow-up and were involved in the
present analysis. The study was approved by the ethical
committee of Jiangsu Provincial Center for Disease
Control and Prevention.
Data collection
With written informed consent, a pre-tested question-
naire was used to collect epidemiologic information by
trained interviewers. The information obtained including
demographic information, lifestyle risk factors, personal
medical history and family history of diabetes (DM-FH).
Anthropometric measurements were conducted at
the time of interview including weight, height, WC and
blood pressure. Body weight and height were measured
by standard methods, and recorded to the nearest
0.1 kg and 0.1 cm, respectively. BMI was calculated as
the weight in kilograms divided by the square of the
height in meters. WC was measured two times at 1 cm
above the umbilicus level at minimal respiration. WHtR
was calculated as dividing WC by height. Systolic blood
pressure (SBP) and diastolic blood pressure (DBP) were
examined 3 times at 30-second intervals by trained
doctors, using a standardized mercury sphygmoman-
ometer on the right arm after resting for 5 minutes in a
sitting position [19].
Blood samples were collected in the morning after at
least 8 hours of overnight fasting. All plasma and serum
samples were frozen at −80°C until laboratory test was
performed. Laboratory tests were conducted in qualified
labs in Jiangsu Provincial Center for Disease Control
and Prevention, including fasting plasma glucose (FPG),
TG, HDL-C. FPG was measured by an enzymatic colori-
metric method with glucose oxidize. HDL-C and TG were
assessed enzymatically using an automatic biochemistry
analyzer (Hitachi Inc, Tokyo, Japan) and commercial
reagents [18].
Diabetes diagnostic criteria
All newly occurred diabetes patients during the follow-up
period were diagnosed according to the criteria of WHO,
1999 [20]: FPG no less than 7 mmol/L (or 126 mg/dL), or
have been diagnosed as diabetes by a county level hospital
or above.
Statistical analysis
Data were entered into the computer double parallel
using Epidata 3.0, cleaned and analyzed using SPSS 17.0.
The start of follow-up was defined as the date of first
Table 1 The epidemiologic characteristic of study
participants by gender
Variables Male (%) Female (%) Total (%)
(N = 1,406) (N = 2,055) (N = 3,461)
Age (years)
Mean ± SD 50.60 ± 9.80 49.95 ± 10.07 50.21 ± 9.97
< 45 421 (29.9%) 700 (34.1%) 1121 (32.4%)
45 ~ 54 513 (36.5%) 706 (34.4%) 1219 (35.2%)
≥55 472 (33.6%) 649 (31.6%) 1121 (32.4%)
SBP (mmHg)
Mean ± SD 126.61 ± 19.57 124.84 ± 19.92 125.56 ± 19.79
DBP (mmHg)
Mean ± SD 81.39 ± 11.26 78.63 ± 10.46 79.75 ± 10.87
FPG (mmol/L)
Mean ± SD 5.11 ± 0.63 5.17 ± 0.64 5.15 ± 0.63
Alcohol drinking
No-drinking 745 (53.0%) 1960 (95.4%) 2705 (78.2%)
Ex-drinking 26 (1.8%) 0 (0%) 26 (0.8%)
Drinking 635 (45.2%) 95 (4.6%) 730 (21.1%)
Smoking history
No-smoking 583 (41.5%) 1918 (93.3%) 2501 (72.3%)
Ex-smoking 155 (11.0%) 11 (0.5%) 166 (4.8%)
Smoking 668 (47.5%) 126 (6.1%) 794 (22.9%)
DM-FH (%) 66 (4.7%) 114 (5.5%) 180 (5.2%)
VAI
I (≤1.047) 528 (37.6%) 320 (15.6%) 848 (24.5%)
II (1.048-) 371 (26.4%) 484 (23.6%) 855 (24.7%)
III (1.643-) 265 (18.8%) 606 (29.5%) 871 (25.2%)
IV (≥2.66) 242 (17.2%) 645 (31.4%) 887 (25.6%)
Diabetes 60 (4.3%) 100 (4.9%) 160 (4.6%)
SD, standard deviation; SBP, systolic blood pressure; DBP, diastolic blood
pressure; FPG, fasting plasma glucose; DM-FH, family history of diabetes;
VAI, visceral adipose index.
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follow-up ended at the time of diabetes occurrence.
Mean and standard deviation (SD) were calculated for
continuous variables. Analysis of variance was used for
comparison between groups if they were in normal dis-
tribution. For variables in skewed distribution, we calcu-
lated their medians and inter-quartile ranges, and used
rank sum test for the comparison between groups. Cat-
egorical variables were calculated for percentages and
chi-square test was used for statistical analysis.
Confounders were selected based on previous know-
ledge on diabetes risk factors and our preliminary ana-
lysis, including age, gender, smoking, alcohol drinking,
SBP, DBP and DM-FH.
According to Amato’s research [13], VAI was defined as:
Male : VAI ¼ WC








Female : VAI ¼ WC








VAI = 1 stands for subjects are healthy, non-obese,
with normal adipose distribution and normal TG and
HDL-C levels.
In the present analysis, VAI was grouped by quartiles
(the cut-off point was selected from general population
without diabetes). According to Cooperative Meta-
analysis Group of China Obesity Task Force, BMI were
divided into three groups, normal (<24 kg/m2), over-
weight (24–27.9 kg/m2) and obesity (≥28 kg/m2) [21].
Cut-off point of WC for men and women were 85 cm
and 80 cm, respectively [21]. WHtR less than 0.5 was
considered as normal [22]. Hazard ratio (HR) and corre-
sponding 95% confidence intervals (CIs) were calculated
by Cox proportional hazard regression model to evaluate
the associations between different body fatness indices
and diabetes risk. Dummy variables were used to calcu-
late HR for each categorical variable. The trend test was
performed by assigning scores to different categorical
variables and treated the categorical variables as con-
tinuous variables in the Cox regression model. Receiver
operating characteristic (ROC) curve was applied to
compare the predictive effect between VAI, WC, WHtR
and BMI for diabetes risk. The area under curve (AUC)
was calculated for comparison between four body fatness
indices. Significant level for statistics analysis was set as
p < 0.05.Results
In total, 1,406 males and 2,055 females were involved in
the present analysis. The median follow-up time was
5.8 years. Table 1 shows the baseline epidemiologic char-
acteristics of 3,461 participants by gender. The average
age of men and women was 50.60 and 49.95 years old,
respectively. Men's smoking and drinking rate was
higher than that of women. No significant difference was
observed in SBP, DBP and FPG between males and fe-
males. But for VAI, we found women were more likely
to have higher VAI than men. During the follow-up, a
total number of 160 newly occurred diabetes cases were
identified during the follow-up period (4.6%), 60 of them
were males and 100 were females.
Table 2 presents the associations between VAI level and dif-
ferent metabolic variables. Significant positive dose–response
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TG, WC, BMI and WHtR (p for trend < 0.001). On the
contrary, HDL-C was observed negatively correlated with
VAI level (p < 0.001).
The incidence of diabetes among study population and
diabetes risk with different body fatness indices are shown
in Table 3. We found that the incidence of diabetes in the
highest VAI group was 6.99%. As compared to individuals
with the lowest VAI, those who had the highest VAI were at
2.55-fold risk of diabetes (95% CI: 1.58-4.11). We observedTable 2 Characteristics of metabolic variables in different VA
I (≤1.047) II (1.048-)
SBP (mmHg)
Male 125.08 ± 19.95 125.43 ± 19.08
Female 119.58 ± 17.50 122.85 ± 18.38
Total 123.00 ± 19.24 123.97 ± 18.72
DBP (mmHg)
Male 79.52 ± 11.35 80.70 ± 11.10
Female 75.13 ± 9.80 77.46 ± 9.65
Total 77.86 ± 10.99 78.87 ± 10.43
FPG (mmol/L)
Male 5.10 ± 0.63 5.02 ± 0.58
Female 5.18 ± 0.66 5.10 ± 0.61
Total 5.12 ± 0.63 5.07 ± 0.60
HDL-C (mmol/L)
Male 1.54 ± 0.37 1.21 ± 0.23
Female 1.65 ± 0.32 1.39 ± 0.26
Total 1.58 ± 0.36 1.31 ± 0.26
TG (mmol/L)
Male 0.87 (0.73-1.03) 1.10(1.25-1.45)
Female 0.74 (0.63-0.88) 0.93(1.05-1.19)
Total 0.82 (0.69-0.99) 1.14(0.99-1.32)
WC (cm)
Male 72.76 ± 7.20 77.23 ± 8.26
Female 69.40 ± 6.87 72.87 ± 7.85
Total 71.50 ± 7.26 74.76 ± 8.31
BMI (kg/m2)
Male 21.15 ± 2.49 22.40 ± 2.84
Female 21.61 ± 2.86 22.37 ± 3.08
Total 21.32 ± 2.64 22.38 ± 2.98
WHtR
Male 0.44 ± 0.04 0.47 ± 0.05
Female 0.45 ± 0.04 0.47 ± 0.05
Total 0.44 ± 0.04 0.47 ± 0.05
SBP, systolic blood pressure; DBP, diastolic blood pressure; FPG, fasting plasma gluc
circumference; BMI, body mass index; WHtR, waist-to-height ratio; VAI, visceral adip
Median and inter quartile range for TG; Mean ± SD for SBP, DBP, FPG, HDL-C, WC, Bpositive trends between diabetes risk and VAI level both
for crude HR (HR = 1.38, 95% CI: 1.19-1.60) and adjusted
HR (HRadj = 1.34, 95% CI: 1.15-1.56).
For BMI, WC and WHtR, significant association was
observed between diabetes and WC (HRadj = 1.48, 95% CI:
1.04-2.10) and WHtR (HRadj = 1.43, 95% CI: 1.03-1.97);
however, an insignificant relationship was observed for dia-
betes with BMI (HRadj = 1.07, 95% CI: 0.83-1.36).
The results of ROC analysis and AUC with its corre-
sponding 95% CIs for VAI, WC, WHtR and BMI areI groups
VAI p for
trendIII (1.643-) IV (≥2.66)
127.04 ± 18.90 131.29 ± 19.56 <0.001
125.06 ± 19.95 128.76 ± 21.32 <0.001
125.67 ± 19.65 129.45 ± 20.87 <0.001
82.22 ± 10.85 85.59 ± 10.58 <0.001
79.23 ± 10.29 80.68 ± 10.97 <0.001
80.14 ± 10.55 82.02 ± 11.08 <0.001
5.14 ± 0.65 5.26 ± 0.67 <0.001
5.13 ± 0.63 5.27 ± 0.65 <0.001
5.13 ± 0.63 5.26 ± 0.65 <0.001
1.09 ± 0.25 0.95 ± 0.27 <0.001
1.22 ± 0.23 1.01 ± 0.20 <0.001
1.18 ± 0.24 0.99 ± 0.23 <0.001
1.77 (1.46-2.09) 2.83 (2.35-3.98) <0.001
1.39 (1.23-1.58) 2.15 (1.81-2.76) <0.001
1.47 (1.28-1.74) 2.35 (1.92-3.08) <0.001
81.11 ± 8.69 84.47 ± 8.52 <0.001
76.57 ± 8.65 80.51 ± 8.80 <0.001
77.95 ± 8.91 81.59 ± 8.90 <0.001
23.47 ± 2.83 24.77 ± 3.06 <0.001
23.38 ± 3.37 24.54 ± 3.17 <0.001
23.41 ± 3.22 24.60 ± 3.14 <0.001
0.49 ± 0.05 0.51 ± 0.05 <0.001
0.49 ± 0.05 0.52 ± 0.06 <0.001
0.49 ± 0.05 0.52 ± 0.06 <0.001
ose; HDL-C, high density lipoprotein cholesterol; TG, triglyceride; WC, waist
ose index.
MI, WHtR.
Table 3 The incidence and HR (95% CI) of diabetes risk with different body fatness indices groups
Variables New cases Total subjects Incidence (%) HRcru (95% CI) HRadj* (95% CI)
VAI
I 23 848 2.71 1 (referent) 1 (referent)
II 30 855 3.50 1.26 (0.73- 2.18) 1.22 (0.71-2.11)
III 45 871 5.17 1.86 (1.12-3.07) 1.75 (1.05-2.92)
IV 62 887 6.99 2.55 (1.58-4.11) 2.21 (1.35-3.61)
HR for trend (p < 0.001) 1.38 (1.19-1.60) 1.34 (1.15-1.56)
BMI (kg/m2)
Normal 93 2247 4.14 1 (referent) 1 (referent)
Overweight 54 985 5.48 1.30 (0.93-1.82) 1.15 (0.81-1.62)
Obesity 13 229 5.68 1.37 (0.76-2.44) 1.10 (0.60-2.00)
HR for trend (p = 0.102) 1.22 (0.96-1.54) 1.07 (0.83-1.36)
WC (cm)
Normal 110 2594 4.24 1 (referent) 1 (referent)
High 50 867 5.77 1.51 (1.09-2.10) 1.48 (1.04-2.10)
WHtR
Normal 89 2224 4.00 1 (referent) 1 (referent)
High 71 1237 5.74 1.48 (1.08-2.02) 1.43 (1.03-1.97)
VAI, visceral adipose index; BMI, body mass index; WC, waist circumference; WHtR, waist-to-height ratio; HR, hazard ratio; CIs, confidence intervals.
*Adjusted for age, gender, SBP, DBP, smoking, alcohol drinking and DM-FH.
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(AUC= 0.62, 95% CI: 0.58-0.66), following by WC (AUC=
0.55, 95% CI: 0.51-0.60), WHtR (AUC= 0.55, 95% CI: 0.50-
0.59) and BMI (AUC= 0.54, 95% CI: 0.49-0.59).
Discussion
In this prospective cohort study, we confirmed that
obesity is an important risk factor of type 2 diabetes
among a Chinese population, and found the increase of
visceral adiposity was positively associated with meta-
bolic disorders and diabetes risk with clear dose–re-
sponse relationships. Compared to other body fatness
indices, VAI was observed to be better in identifying the
risk of diabetes than BMI, WC and WHtR.
The strong relationship between obesity and diabetes
has been reported by many studies. Some researchers
even use the term “diabesity” to describe their close as-
sociations [23]. Yang SL et al. found that people with
large WC has 3.79-fold risk of diabetes than those whoseTable 4 Comparison of AUC and corresponding 95% CI
between VAI, WC, WHtR and BMI
Variables Standard error AUC (95% CI) p-Value
VAI 0.02 0.62 (0.58-0.66) <0.001
WC 0.02 0.55 (0.51-0.60) 0.027
WHtR 0.02 0.55 (0.50-0.59) 0.046
BMI 0.02 0.54 (0.49-0.59) 0.072
AUC, area under curve; VAI, visceral adipose index; BMI, body mass index; WC,
waist circumference; WHtR, waist-to-height ratio; CIs, confidence intervals.WC were normal [24]. Yang WY et al. reported that the
prevalence of diabetes in overweight group was 43%
higher than that of normal people, and about 70% dia-
betes patients whose BMI were more than 25 kg/m2 [3].
Clinical trials showed that even 5% weight loss was suffi-
cient to prevent most obese subjects from impaired glu-
cose tolerance and developing diabetes [25], especially
for abdominal obesity.
The main harm caused by obesity is visceral adipose ac-
cumulation [26]. He et al. found that among men with
normal WC, the incidence of MS in visceral obese people
was significantly higher than that of normal group [27].
Fox et al. reported that both subcutaneous abdominal adi-
pose tissue (SAT) and VAT were associated with increased
odds ratio (OR) of MS. In women, the OR for VAT (OR =
4.7) was stronger than that for SAT (OR = 3.0); similar dif-
ference was shown for men (OR for VAT = 4.2; OR for
SAT = 2.5) [8]. The molecular mechanism underlying this
is unclear yet. It has been suggested that compared with
subcutaneous fat, high visceral fat produces more free
fatty acid, thus will increase the risk of IR and diabetes
[8,28]. Fontana et al. reported that visceral adipose can se-
crete a large number of inflammatory cytokines, cells and
adipokines, which may play important roles in the occur-
rence of IR and diabetes [26]. Liu et al. observed that visfa-
tin, an adipokine which mainly produced by visceral
adipose had the insulin-like effect, and has been proved to
aggravate IR [29]. Moreover, as Masuzaki found in trans-
genic animals experiments, when 11 beta hydroxysteroid
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in fat cells, it would cause visceral adiposity and a series of
metabolic disorders, which indicates that 11βHSD- 1 en-
zyme may have the same molecular basis with visceral
obesity and metabolic disorders [30]. However, the mech-
anism between visceral adiposity and metabolic disorders
still needs to be further elucidated.
Although visceral fat has been found independently as-
sociated with IR and diabetes, and could be used to esti-
mate the risk of diabetes, it’s not easy to measure body
VAT volumes. MRI and CT have been considered as the
gold standard for VAT measurements, but it is obviously
they are not suitable for large epidemiological studies
because of the high cost and inconvenience. Different
from direct VAT determination, VAI could be easily con-
ducted in large-scale epidemiological studies and has
been suggested as a useful surrogate marker of VAT.
VAI includes physical (BMI and WC) and metabolic
(TG and HDL-C) parameters, it may indirectly reflects
other non-classical risk factors, i.e. altered production of
adipokine, increased lipolytic activity and plasma-free
fatty acids. Recently reported by Al-Daghri et al., VAI
was negatively related with adiponectin value, this was
the first report for the direct relations of VAI with adi-
pose tissue secretion [31]. Some researches have proved
that VAI could be used to predictive individual risk of
IR, MS, acromegaly, cardiovascular disease (CVD) and
diabetes [14,32-34]. Consistent with previous researches
[14,31], our study also indicated that VAI is a useful sur-
rogate marker to identify the risk of diabetes; individuals
with high VAI were accompanied with increased risk of
metabolic disorders and diabetes. The risk of getting dia-
betes at the highest VAI group was 2.55 folds higher as
compared to the lowest VAI group.
According to the results of ROC analysis, the largest
AUC was observed for VAI (AUC = 0.620, p < 0.001), fol-
lowing by WC, WHtR and BMI. Except VAI, AUC for
other body fatness indices were all close to 0.5, which
means the relatively lower predictive discriminatory
power. Moreover, we observed positive trends between
diabetes risk and VAI levels (HR = 1.38, 95% CI: 1.19-
1.60), similar association was observed for WC (HRadj =
1.48, 95% CI: 1.04-2.10) and WHtR (HRadj = 1.43, 95%
CI: 1.03-1.97), whereas only an insignificant adjusted HR
was observed for BMI (HRadj = 1.07, 95% CI: 0.83-1.36).
These findings suggested that VAI may be better in iden-
tifying diabetes risk. However, the ability of VAI in iden-
tifying diabetes risk was not found to be superior to
WHtR in previous research which conducted among
Tehran people [14]. This difference might be attributed
to different study populations. It has reported that com-
pared with Caucasians, Asians may have significantly
higher risk of type 2 diabetes and CVDs despite substan-
tially lower BMI [35]. Wang et al. found that Chinesemen tend to have higher levels of FPG and DBP and sig-
nificantly lower levels of HDL-C than Europeans [36].
Similar result was also found for Chinese women by
Lear et al. [37]. In additional, several researches have
proved that Chinese people may have higher VAT levels
than European with a given body size [38,39]. Variations
in lifestyle may also have effect on the relationship be-
tween VAT and diabetes risk among different populations
besides hereditary factors [40]. To date, few published
studies have explored relationship between VAI and dia-
betes risk and compared different body fatness indices
with diabetes risk. Thus, the efficiency of VAI in predict-
ing the risk of chronic diseases including diabetes still
needs further verification from studies in different areas
and different ethnicities.
Some limitations of our study need to be discussed.
Firstly, because of the relative short time of follow-up
and hence the relatively small number of new diabetes
cases, the statistical power to examine the associations
between VAI and diabetes may be insufficient. Secondly,
IR was not measured in the present analysis therefore
we were not able to directly examine the associations be-
tween VAI and IR. Thirdly, we did not examine 2-hour
postprandial glucose, which may lead to the under diag-
nosis of some diabetic patients. Finally, residual con-
founders, an innate limitation of observational studies,
could not be eliminated thus may increase the possibility
that uncontrolled or inadequately measured confounders
affected our results.
Despite these limitations, our study confirmed that
obesity is an important risk factor of diabetes among
Chinese population and found visceral adiposity is more
important in disease occurrence. Compared to other in-
dices for body fatness measurements, VAI is a good and
convenience surrogate marker for visceral adipose meas-
urement and could be used in identifying the risk of dia-
betes in large-scale epidemiologic studies.
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